Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Arcturus Therapeutics Holdings Inc. Stock Research

ARCT

26.92USD+0.41(+1.55%)Market Closed
Watchlist

Market Summary

USD26.92+0.41
Market Closed
1.55%

ARCT Alerts

ARCT Stock Price

ARCT RSI Chart

ARCT Valuation

Market Cap

715.4M

Price/Earnings (Trailing)

8.91

Price/Sales (Trailing)

2.7

EV/EBITDA

156.39

Price/Free Cashflow

5.69

ARCT Price/Sales (Trailing)

ARCT Profitability

EBT Margin

72.38%

Return on Equity

33.8%

Return on Assets

23.63%

Free Cashflow Yield

17.58%

ARCT Fundamentals

ARCT Revenue

Revenue (TTM)

264.5M

Revenue Y/Y

-61.17%

Revenue Q/Q

-86.9%

ARCT Earnings

Earnings (TTM)

80.3M

Earnings Y/Y

-143.7%

Earnings Q/Q

-203.54%

Price Action

52 Week Range

37.75
(Low)(High)

Last 7 days

-8.4%

Last 30 days

-17.4%

Last 90 days

12.5%

Trailing 12 Months

86.7%

ARCT Financial Health

Current Ratio

4.71

ARCT Investor Care

Shares Dilution (1Y)

0.53%

Diluted EPS (TTM)

3

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for ARCT

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-01
Chivukula Pad
sold
-157,264
31.4527
-5,000
chief scientific officer & coo
2023-08-15
SASSINE ANDY
acquired
21,248
17.374
1,223
chief financial officer
2023-08-01
Chivukula Pad
sold
-174,550
34.91
-5,000
chief scientific officer & coo
2023-07-14
Kummerfeld Keith C
sold
-243,880
35.00
-6,968
see remarks
2023-07-14
Kummerfeld Keith C
acquired
62,408
8.95642
6,968
see remarks
2023-07-14
Chivukula Pad
sold
-875,250
35.01
-25,000
chief scientific officer & coo
2023-07-03
Chivukula Pad
sold
-143,750
28.75
-5,000
chief scientific officer & coo
2023-06-01
Chivukula Pad
sold
-135,800
27.16
-5,000
chief scientific officer & coo
2023-05-11
Chivukula Pad
sold
-239,652
30.24
-7,925
chief scientific officer & coo
2023-05-10
Chivukula Pad
sold
-512,250
30.00
-17,075
chief scientific officer & coo

1–10 of 49

Which funds bought or sold ARCT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-08-24
Alberta Investment Management Corp
new
-
275,385
275,385
-%
2023-08-22
VIRGINIA RETIREMENT SYSTEMS ET AL
new
-
321,216
321,216
-%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-2.56
117,446
825,496
-%
2023-08-21
OSAIC HOLDINGS, INC.
reduced
-7.53
4,606
47,888
-%
2023-08-16
Nuveen Asset Management, LLC
added
27.11
1,850,360
5,401,360
-%
2023-08-15
LAZARD ASSET MANAGEMENT LLC
added
28.29
119,000
341,000
-%
2023-08-15
WELLS FARGO & COMPANY/MN
reduced
-4.38
554,612
4,405,100
-%
2023-08-15
ALLIANCEBERNSTEIN L.P.
added
255
1,778,570
2,325,090
-%
2023-08-15
Formidable Asset Management, LLC
unchanged
-
45,000
429,000
0.09%
2023-08-15
GOLDMAN SACHS GROUP INC
added
19.76
3,273,000
10,833,200
-%

1–10 of 46

Latest Funds Activity

Are funds buying ARCT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ARCT
No. of Funds

Schedule 13G FIlings of Arcturus Therapeutics Holdings

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
5.46%
1,450,425
SC 13G
Feb 08, 2023
state street corp
8.50%
2,257,846
SC 13G/A
Feb 03, 2023
sumitomo mitsui trust holdings, inc.
5.45%
1,449,060
SC 13G/A
Feb 01, 2023
federated hermes, inc.
16.00%
4,239,554
SC 13G/A
Jan 31, 2023
blackrock inc.
7.1%
1,884,885
SC 13G/A
Apr 11, 2022
state street corp
12.20%
3,217,957
SC 13G/A
Feb 14, 2022
nikko asset management americas, inc.
5.15%
1,357,472
SC 13G
Feb 14, 2022
federated hermes, inc.
14.02%
3,694,929
SC 13G
Feb 14, 2022
price t rowe associates inc /md/
0.0%
15,039
SC 13G/A
Feb 11, 2022
state street corp
7.80%
2,056,074
SC 13G

Recent SEC filings of Arcturus Therapeutics Holdings

View All Filings
Date Filed Form Type Document
Sep 05, 2023
4
Insider Trading
Sep 01, 2023
144
Notice of Insider Sale Intent
Aug 17, 2023
4
Insider Trading
Aug 14, 2023
8-K
Current Report
Aug 07, 2023
10-Q
Quarterly Report
Aug 07, 2023
424B5
Prospectus Filed
Aug 07, 2023
8-K
Current Report
Aug 03, 2023
4
Insider Trading
Aug 03, 2023
4
Insider Trading
Aug 03, 2023
4
Insider Trading

ARCT Fair Value

Loading...

Peers (Alternatives to Arcturus Therapeutics Holdings)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
271.1B
56.0B
3.50% 10.46%
31.22
4.84
-2.31% -31.27%
258.4B
1.8B
-3.35% 26.15%
-149.17
142.72
69.45% 14.65%
91.3B
9.5B
1.11% 26.35%
27.14
9.61
13.83% 5.33%
88.1B
12.7B
-2.05% 20.27%
20.49
6.95
-10.94% -24.40%
21.7B
1.2B
-8.20% -15.77%
-20.42
17.55
39.94% -8.44%
11.2B
1.0B
5.15% 8.54%
-12.29
11.11
20.15% -79.16%
10.5B
2.1B
-3.19% 8.81%
12.04
4.97
18.01% 38.16%
MID-CAP
3.0B
225.6M
0.06% -27.49%
-5.4
13.27
-2.11% 21.02%
2.9B
-
-11.82% 158.82%
-8.93
-
- -28.88%
2.6B
402.9M
1.47% -16.95%
-3.63
6.49
20.50% -42.46%
2.1B
27.2M
-3.08% -49.09%
-2.89
78.22
- -14.43%
SMALL-CAP
3.1B
-
-6.35% -39.40%
-7.31
33.28
34.30% -149.91%
1.3B
302.9M
-15.88% -2.65%
11.18
4.26
77.72% 112.02%
289.9M
152.5M
-10.34% 48.10%
38.91
1.9
127.84% 103.41%
28.7M
-
0.62% 3389.00%
-0.62
-
- -31.51%

Arcturus Therapeutics Holdings News

Defense World
Arcturus Therapeutics (NASDAQ:ARCT) Receives Buy Rating from ....
Defense World,
18 hours ago
Marketscreener.com
Marketscreener.com

Returns for ARCT

Cumulative Returns on ARCT

-13.1%


10-Year Cumulative Returns

-2.8%


7-Year Cumulative Returns

22.4%


5-Year Cumulative Returns

-12.9%


3-Year Cumulative Returns

Risks for ARCT

What is the probability of a big loss on ARCT?

100%


Probability that Arcturus Therapeutics Holdings stock will be more than 20% underwater in next one year

100%


Probability that Arcturus Therapeutics Holdings stock will be more than 30% underwater in next one year.

83.1%


Probability that Arcturus Therapeutics Holdings stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ARCT drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Arcturus Therapeutics Holdings was unfortunately bought at previous high price.

Drawdowns

Financials for Arcturus Therapeutics Holdings

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue-5.9%264,466,000281,040,000205,999,00051,500,00040,568,00015,476,00012,359,0008,803,0008,699,0009,020,0009,539,00010,269,00011,254,00019,085,00020,789,00025,398,00025,503,00017,736,00015,753,00011,618,0009,544,000
Operating Expenses8.2%220,440,000203,729,000193,822,000198,420,000204,502,000211,041,000215,211,000205,092,000172,105,000128,748,00081,063,00061,528,00049,191,00047,552,00046,302,00040,805,00037,650,00039,383,00037,564,00040,474,00049,832,000
  S&GA Expenses4.5%51,335,00049,103,00046,071,00045,017,00043,389,00042,438,00041,451,00039,679,00034,391,00028,769,00023,217,00015,974,00014,283,00013,319,00012,662,00014,312,00014,241,00019,018,00020,582,00024,086,00032,932,000
  R&D Expenses9.4%169,105,000154,626,000147,751,000153,403,000161,113,000168,603,000173,760,000165,413,000137,714,00099,979,00057,846,00045,554,00034,908,00034,233,00033,640,00026,493,00023,409,00020,365,00016,982,00016,388,00016,900,000
EBITDA-100.0%-208,125,00012,984,000-----19,845,000-19,952,000-20,104,000-20,152,000-20,694,000-20,519,000-20,298,000-20,410,000-20,368,666-20,366,000-20,478,000-21,057,000--
EBITDA Margin-100.0%-0.740.06-----2.25-2.29-2.23-2.11-2.02-1.82-1.06-0.98-0.80-0.80-1.15-1.34--
Interest Expenses-6.8%2,560,0002,746,000813,000755,000698,000684,000684,0001,092,000912,000692,000751,000356,000531,000752,000691,000677,333680,000668,000146,000--
Earnings Before Taxes-103.8%-2,232,00058,588,00010,644,000--145,464,000-204,676,000-203,674,000--------------
EBT Margin-100.0%-0.720.05-----2.47-2.50-2.42-2.28-2.12-1.94-1.14-1.05-0.86-0.85-1.23-1.38--
Net Income-27.8%80,285,000111,272,0009,349,000-146,661,000-165,479,000-198,497,000-203,674,000-196,115,000-163,035,000-118,717,000-72,148,000-52,033,000-38,462,000-28,884,000-25,991,000-16,013,000-12,833,000-22,098,000-21,785,000-28,406,000-39,800,000
Net Income Margin-100.0%-0.400.05-2.85-4.08-12.83-16.48-22.28-18.74-13.16-7.56-5.07-3.42-1.51-1.25------
Free Cashflow-100.0%-38,855,00024,267,000-175,800,000-149,627,000-146,531,000-138,449,000-102,163,000-100,055,000-75,671,000-44,603,000-45,127,000-31,811,000-13,774,000-7,263,000------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22018Q4
Assets-8.5%43147145029433734239343544948147632315072.0082.0087.0071.0044.00
  Current Assets-9.3%38542540324729232737942143847046831414264.0074.0079.0063.0042.00
    Cash Equivalents-1.4%32332839223828332037341443446746330713659.0071.0074.0056.0037.00
  Net PPE0.7%13.0013.0012.0011.009.008.006.005.003.003.003.003.003.003.002.002.002.002.00
Liabilities2.7%14514218014816615716517514312980.0061.0057.0055.0056.0051.0049.0031.00
  Current Liabilities0.2%90.0090.0012776.0093.0010710011871.0053.0050.0028.0023.0022.0021.0022.0016.0013.00
    LT Debt, Current---61.0028.0027.0024.0022.00---1.00-------
    LT Debt, Non Current----32.0036.0039.0041.0042.0056.0058.0014.0015.0015.0015.0015.0010.0010.0010.00
Shareholder's Equity-13.4%28532927014617118522825930635339726293.0017.0026.0036.0022.0014.00
  Retained Earnings-18.3%-339-287-338-455-420-398-347-308-254-200-143-112-91.71-81.44-71.67-60.68-53.25-44.87
  Additional Paid-In Capital1.4%62561760860159158357656856055354037418598.0097.0097.0075.0058.00
Shares Outstanding0.1%27.0027.0027.0026.0026.0026.0026.0026.0026.0026.0026.0023.0019.0015.0012.0013.0010.0010.00
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Last 12 Months)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations194.0%132,78945,16131,993-170,763-145,010-141,132-135,043-99,178-98,402-73,953-42,861-43,767-30,726-12,892-6,445-4,670-8,629-23,958-20,760-27,180-16,404
  Share Based Compensation3.5%32,53131,42230,61131,59929,03329,29928,91524,22319,34112,9026,7644,7353,1302,4321,9821,6911,8951,9891,2592,348332
Cashflow From Investing-11.6%-7,038-6,306-7,726-5,037-4,617-5,399-3,406-2,985-1,653-1,718-1,742-1,360-1,085-882-8181,7669,74813,35222,13431,29224,084
Cashflow From Financing-0.5%-30,722-30,559-2,859-3971,5151,34048,016210,987397,518483,039436,145277,978112,08235,30541,90762,39819,706-10,204-76.00702

ARCT Income Statement

2023-06-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenue:    
Total revenue$ 10,519$ 27,093$ 90,804$ 32,337
Operating expenses:    
Research and development, net52,66838,189104,43683,082
General and administrative13,22510,99326,98721,723
Total operating expenses65,89349,182131,423104,805
Loss from operations(55,374)(22,089)(40,619)(72,468)
Loss from equity-method investment (131) (515)
Gain (loss) from foreign currency1491,217(179)1,375
Gain on debt extinguishment  33,953 
Finance income (expense), net3,252(560)5,729(1,124)
Net loss before income taxes(51,973)(21,563)(1,116)(72,732)
Provision for income taxes577 680 
Net loss$ (52,550)$ (21,563)$ (1,796)$ (72,732)
Net loss per share:    
Basic$ (1.98)$ (0.82)$ (0.07)$ (2.75)
Diluted$ (1.98)$ (0.82)$ (0.07)$ (2.75)
Weighted-average shares outstanding:    
Basic26,56326,42526,55726,401
Diluted26,56326,42526,55726,401
Comprehensive loss:    
Net loss$ (52,550)$ (21,563)$ (1,796)$ (72,732)
Comprehensive loss(52,550)(21,563)(1,796)(72,732)
Collaboration Revenue [Member]    
Revenue:    
Total revenue9,565$ 27,09389,294$ 32,337
Grant Revenue [Member]    
Revenue:    
Total revenue$ 954 $ 1,510 

ARCT Balance Sheet

2023-06-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 323,471$ 391,883
Restricted cash55,000 
Accounts receivable2,7992,764
Prepaid expenses and other current assets3,9748,686
Total current assets385,244403,333
Property and equipment, net12,72212,415
Operating lease right-of-use asset, net30,55332,545
Non-current restricted cash2,1272,094
Total assets430,646450,387
Current liabilities:  
Accounts payable13,6197,449
Accrued liabilities28,76330,232
Current portion of long-term debt 60,655
Deferred revenue47,96328,648
Total current liabilities90,345126,984
Deferred revenue, net of current portion25,72520,071
Operating lease liability, net of current portion28,11130,216
Other non-current liabilities1,2902,804
Total liabilities145,471180,075
Stockholders’ equity  
Common stock, $0.001 par value; 60,000 shares authorized; issued and outstanding shares were 26,574 at June 30, 2023 and 26,555 at December 31, 20222727
Additional paid-in capital625,085608,426
Accumulated deficit(339,937)(338,141)
Total stockholders’ equity285,175270,312
Total liabilities and stockholders’ equity$ 430,646$ 450,387

About Arcturus Therapeutics Holdings